Prescriber survey to evaluate the awareness to risk minimisation measures for mitoxantrone-containing medicinal products in the treatment of patients with highly active relapsing multiple sclerosis associated with rapidly evolving disabilityFirst published 05/11/2019 Last updated 04/10/2021 EU PAS number: EUPAS32142StudyOngoing